Journal of Multiple Sclerosis

ISSN - 2376-0389
NLM - 101654564

Leslie A Hammer

Leslie A Hammer


  • Research Article
    Low Dose Naltrexone Treatment of Established Relapsing-Remitting Experimental Autoimmune Encephalomyelitis

    Author(s): Leslie A Hammer, Ian S Zagon and Patricia J McLaughlinLeslie A Hammer, Ian S Zagon and Patricia J McLaughlin

    Background: Relapse-remitting multiple sclerosis is a chronic disorder that affects more than 400,000 individuals in the United States, often reducing their quality of life, increasing medical expenses, and limiting mobility. This study examines modulation of the opioid growth factor (OGF) – OGF receptor (OGFr) axis by low dosages of naltrexone (LDN) as a disease modifying therapy using a mouse model of relapse-remitting experimental autoimmune encephalomyelitis (RR-EAE). Methods: RR-EAE was induced by immunization of SJL/J mice with proteolipid protein 139-151. After two days of clinical disease, mice were injected intraperitoneally with 0.1 mg/kg naltrexone (LDN) or saline for 40 days. Behavior was observed daily, and periodically, mice were euthanized and spinal cords collected for neuropathological evaluation of glia, T lymphocyte .. View More»


Relevant Topics